第41回 日本泌尿器科学会中部総会シンポジウム 「進行腎癌に対する新しい治療開発の試み」 - 司会にあたって-

Abstract

Advanced (metastatic) renal cell carcinoma has a poor prognosis, and patients seldom survive for more than a few years despite aggressive therapy using conventional modalities. The treatment of metastatic lesions arising from renal cell carcinoma is a difficult and challenging problem. Recently, several kinds of new therapies including immunotherapy have been developed extensively for metastatic renal cell carcinoma, primarily because of the absence of an effective standard therapy. The present paper is a summary of 8 articles presented at the symposium on "Studies on new therapies in advanced renal cell carcinoma", 41st Annual Meeting of Center Section of Japanese Urological Association held in November, 1991. The present status and problems in treatment of advanced renal cell carcinoma, biological characters of this disease, immunotherapy including interferon therapy and LAK-therapy, monoclonal antibody to human renal cell carcinoma, intrinsic multidrug-resistance, and oncogenes (anti-IL-6 therapy) were discussed.